Synopsis: Sai Life Sciences Limited reported strong FY26 performance with revenue rising 25.7 percent to Rs. 2,129 crore, while net profit surged 105 percent to Rs. 349 crore. Growth was driven by higher demand for contract research and manufacturing services, operational scaling, and improved margin expansion across CRDMO operations.
Sai Life Sciences has a total market capitalization of Rs. 20,449.67 crore, according to data on the NSE. Sai Life Sciences shares were trading at Rs. 964 apiece on the National Stock Exchange, down by 13.35 percent; the stock has declined around 14.49 percent over the last five sessions, while it has gone down about 1.76 percent in the 30 days. Over a six-month period, the stock has given a return of 9.56 percent, whereas on a year-on-year basis it has increased nearly 27.61 percent, reflecting mixed overall performance. The stock’s 52-week high was Rs. 1139.40 and 52-week low was Rs. 707.
Sai Life Sciences Limited reported consolidated financial results for the quarter and financial year ended March 31, 2026. The company posted revenue from operations of Rs. 602.14 crore in Q4FY26 compared to Rs. 579.51 crore in Q4FY25, reflecting growth of around 3.9 percent year-on-year. Quarter over quarter, revenue also improved from Rs. 556.46 crore reported in Q3FY26.
Total income for the quarter stood at Rs. 617.66 crore in Q4FY26 compared to Rs. 589.11 crore in the corresponding quarter last year, registering growth of around 4.8 percent year-on-year. The increase was mainly supported by higher contribution from contract manufacturing services and stable demand from pharmaceutical and biotechnology clients.
On the profitability front, the company reported net profit of Rs. 104.24 crore in Q4FY26 compared to Rs. 88.27 crore in Q4FY25, reflecting growth of around 18 percent year-on-year. Quarter over quarter, profit also improved marginally from Rs. 100.38 crore reported in Q3FY26. Profit before tax stood at Rs. 139.23 crore in Q4FY26 compared to Rs. 118.80 crore in Q4FY25, reflecting growth of around 17.2 percent year-on-year. The improvement in profitability was mainly driven by better operating leverage, manufacturing scale-up and improved execution across CRDMO operations.
One of the major factors supporting margins during the quarter was controlled expense growth relative to revenue expansion. Total expenses increased to Rs. 478.72 crore in Q4FY26 compared to Rs. 470.31 crore in Q4FY25, reflecting relatively moderate growth despite higher business activity.
For the full financial year FY26, Sai Life Sciences reported revenue from operations of Rs. 2,129.49 crore compared to Rs. 1,694.57 crore in FY25, reflecting strong growth of around 25.7 percent year-on-year. Net profit for FY26 surged sharply to Rs. 348.91 crore compared to Rs. 170.13 crore in FY25, registering growth of around 105 percent year-on-year.
Profit before tax for FY26 stood at Rs. 466.19 crore compared to Rs. 227.70 crore in FY25. Earnings per share (EPS) for FY26 improved significantly to Rs. 16.63 compared to Rs. 8.83 reported in the previous financial year.
A major factor supporting profitability during FY26 was strong operational scaling and margin expansion. Total income increased to Rs. 2,241.62 crore compared to Rs. 1,731.35 crore in FY25, while profit before tax nearly doubled during the year. The company benefited from rising demand for outsourced pharmaceutical research and manufacturing services from global biotech and pharma companies.
The company also recognized exceptional expenses of around Rs. 8.01 crore during FY26 linked to revised labour code regulations notified by the Government of India. The expense was related to increased gratuity and compensated absence liabilities. Despite this one-time impact, profitability improved strongly during the year.
Another major development during FY26 was the successful completion of the company’s IPO in December 2025. Sai Life Sciences raised approximately Rs. 950 crore through a fresh issue of shares and utilized around Rs. 72 crore towards repayment or prepayment of borrowings, while the remaining proceeds were allocated toward general corporate purposes.
Sai Life Sciences Limited, incorporated in 1999, operates in the contract research, development and manufacturing (CRDMO) segment for pharmaceutical and biotechnology companies globally. The company provides discovery, development and manufacturing solutions across the drug lifecycle.
The pharmaceutical outsourcing industry continues benefiting from increasing drug development activity, rising outsourcing by innovator companies and growing demand for cost-efficient research and manufacturing services. However, profitability remains sensitive to regulatory compliance, client concentration and global pharmaceutical spending trends.
Overall, Sai Life Sciences reported strong FY26 revenue and profitability growth supported by operational expansion, manufacturing scale-up and strong demand across CRDMO services. Going forward, capacity utilization, client additions, global outsourcing trends and execution efficiency will remain key factors influencing the company’s future performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
